grey market glp-1 Analogues Size, Share & Growth Drivers By 2034 GLP-1 now considered on the

digestive health

A population-based cohort study of nearly 114,000 patients with T2D found that use of GLP-1s, compared with SGLT-2 inhibitors, was associated with a 27% higher relative risk of being diagnosed with GERD and a 55% higher relative risk of GERD-related complications

Today, we announced our investigational glucagon/GLP-1 dual receptor agonist achieved key measures of success at 48 weeks in our IMPACT Phase 2b trial and recent interactions with the FDA have resulted in alignment on the parameters for a registrational Phase 3 trial

This in-depth look at Found covers pricing, insurance, coaching, and medication access

Wondering can you change your ozempic shot day

The good news: caffeine itself doesn't block GLP-1 medications, but timing and stomach sensitivity matter for your treatment success